PB1983: TRIAL-IN-PROGRESS: PHASE II STUDY OF PHE885, A B-CELL MATURATION ANTIGEN-DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN ADULTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

• N. Munshi,
• A. Spencer,
• M. S. Raab,
• A. Masood,
• M. Martinez-Prieto,
• J. Chu,
• S. Iida,
• S. Lonial,
• M. A. Dimopoulos

Affiliations

N. Munshi

1 Dana-Farber Cancer Institute, Harvard University, Boston, United States of America

A. Spencer

2 Monash University, Melbourne, Australia

M. S. Raab

3 Universitätsklinikum Heidelberg, Heidelberg, Germany

A. Masood

4 Novartis Pharmaceuticals Corporation, East Hanover, United States of America

M. Martinez-Prieto

4 Novartis Pharmaceuticals Corporation, East Hanover, United States of America

J. Chu

4 Novartis Pharmaceuticals Corporation, East Hanover, United States of America

S. Iida

5 Nagoya City University, Mizuho-ku, Nagoya City, Japan

S. Lonial

6 Winship Cancer Insitute, Emory University, Atlanta, United States of America

M. A. Dimopoulos

7 National and Kapodistrian University of Athens, Athens, Greece